Tansey Baldwin Colleen, Zwahlen Courtney H, Kirschner Steven, Nakamura Reid K
Inland Valley Veterinary Specialists and Emergency CenterUplandCaliforniaUSA.
Southern California Veterinary Specialty HospitalIrvineCaliforniaUSA.
Vet Med Sci. 2016 Feb 23;2(3):147-153. doi: 10.1002/vms3.26. eCollection 2016 Aug.
The objective of the study was to assess the carboplatin sustained-release (CSR) as an injectable, biodegradable polymer system designed to uniformly release carboplatin over 30 days at a dose of 350 mg m. The study involved seven client-owned dogs with histologically or cytologically confirmed neoplasia that were treated with CSR intramuscularly. Platinum levels were measured at days 0, 7, 14, 21 and 28. Complete blood cell (CBC) counts, body weight, local toxicity and side effects were also evaluated at the time of platinum measurement at days 0, 7, 14, 21 and 28. CSR released carboplatin steadily over 30 days. Neutropenia was noted as Grade 3 in one dog (14%) and Grade 4 in two dogs (29%) at day 14, and Grade 4 in one dog (14%) at day 21. Thrombocytopenia was noted as Grade 2 in four dogs (57%), Grade 3 in one dog (14%) and Grade 4 in one dog (14%) at day 14; Grade 2 in two dogs (29%) and Grade 3 in one dog (14%) at days 21 and 28. Grade 1 lethargy in one dog (14%) and Grade 1 nausea in dog (14%) occurring within 7 days after administration. No obvious local injection site reactions were noted. CSR administered at 350 mg m intramuscularly resulted in a steady release over 30 days. Myelosuppression (Grade 4) was noted in 86% of patients. CSR released the drug slowly and steadily, however additional studies are needed to assess acceptable dosage requirements.
该研究的目的是评估卡铂缓释制剂（CSR），它是一种可注射的、可生物降解的聚合物系统，设计用于以350mg/m²的剂量在30天内均匀释放卡铂。该研究涉及7只客户拥有的组织学或细胞学确诊为肿瘤的犬，对其进行了CSR肌肉注射治疗。在第0、7、14、21和28天测量铂水平。在第0、7、14、21和28天测量铂水平时，还评估了全血细胞（CBC）计数、体重、局部毒性和副作用。CSR在30天内稳定释放卡铂。在第14天，1只犬（14%）出现3级中性粒细胞减少，2只犬（29%）出现4级中性粒细胞减少；在第21天，1只犬（14%）出现4级中性粒细胞减少。在第14天，4只犬（57%）出现2级血小板减少，1只犬（14%）出现3级血小板减少，1只犬（14%）出现4级血小板减少；在第21天和28天，2只犬（29%）出现2级血小板减少，1只犬（14%）出现3级血小板减少。1只犬（14%）在给药后7天内出现1级嗜睡，1只犬（14%）出现1级恶心。未观察到明显的局部注射部位反应。以350mg/m²肌肉注射CSR可在30天内稳定释放。86%的患者出现骨髓抑制（4级）。CSR缓慢且稳定地释放药物，然而需要进一步研究来评估可接受的剂量要求。
